昆明理工大学学报(自然科学版)

参考文献

[1] Wei S C,Duffy C R,Allison J P.Fundamental mechanisms of immune checkpoint blockade therapy[J].Cancer discovery,2018,8(9):1069-1086.

[2] Lu Y C,Jia L,Zheng Z,et al.Single-cell transcriptome analysis reveals gene signatures associated with T-cell persistence following adoptive cell therapy[J].Cancer immunology research,2019.

[3] Gross G,Eshhar Z.Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment:counteracting off-tumor toxicities for safe CAR T cell therapy[J].Annual review of pharmacology and toxicology,2016,56:59-83.

[4] Pardoll D M.The blockade of immune checkpoints in cancer immunotherapy[J].Nature Reviews Cancer,2012,12(4):252-264.

[5] Baumeister S H,Freeman G J,Dranoff G,et al.Coinhibitory pathways in immunotherapy for cancer[J].Annual review of immunology,2016,34:539-573..

[6] Kong B Y,Bolton H,Silveira P A,et al.On the Other Side:Manipulating the Immune Checkpoint Landscape of Dendritic Cells to Enhance Cancer Immunotherapy[J].Frontiers in oncology,2019,9:50.

[7] Song Y,Li Z,Xue W,et al.Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy[J].Immunotherapy,2019,11(6):515-529.

[8] Kamphorst A O,Wieland A,Nasti T,et al.Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent[J].Science,2017,355(6332):1423-1427.

[9] Larkin J,Chiarion-Sileni V,Gonzalez R,et al.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma[J].New England journal of medicine,2015,373(1):23-34.

[10] Johnson L A,June C H.Driving gene-engineered T cell immunotherapy of cancer[J].Cell research,2017,27(1):38-58.

[11] Zhou H,Luo Y,Zhu S,et al.The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor-T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis[J].BMC cancer,2018,18(1):929.

[12] Sadelain M,Brentjens R,Rivière I.The basic principles of chimeric antigen receptor design[J].Cancer discovery,2013,3(4):388-398.

[13] Zhao Z,Condomines M,van der Stegen S J C,et al.Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells[J].Cancer cell,2015,28(4):415-428.

[14] Li W,Song X,Jin Y,et al.CARTs for Solid Tumors:Feasible or Infeasible?[J].Oncology research and treatment,2017,40(9):540-546.

[15] Pettitt D,Arshad Z,Smith J,et al.CAR-T cells:a systematic review and mixed methods analysis of the clinical trial landscape[J].Molecular Therapy,2018,26(2):342-353.

[16] Chmielewski M,Abken H.TRUCKs:the fourth generation of CARs[J].Expert opinion on biological therapy,2015,15(8):1145-1154.

[17] Van Schandevyl S,Kerre T.Chimeric antigen receptor T-cell therapy:design improvements and therapeutic strategies in cancer treatment[J].Acta Clinica Belgica,2018,15:1-7.

[18] Zhen A,Peterson C W,Carrillo M A,et al.Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS[J].PLoS pathogens,2017,13(12):e1006753.

[19] Jackson H J,Rafiq S,Brentjens R J.Driving CAR T-cells forward[J].Nature reviews Clinical oncology,2016,13(6):370.

[20] Kawalekar O U,O’Connor R S,Fraietta J A,et al.Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells[J].Immunity,2016,44(2):380-390.

[21] Allahverdiyev A,Tari G,Bagirova M,et al.Current Approaches in Development of Immunotherapeutic Vaccines for Breast Cancer[J].Journal of breast cancer,2018,21(4):343-353.

[22] Melero I,Gaudernack G,Gerritsen W,et al.Therapeutic vaccines for cancer:an overview of clinical trials[J].Nature reviews Clinical oncology,2014,11(9):509.

[23] Pilla L,Ferrone S,Maccalli C.Methods for improving the immunogenicity and efficacy of cancer vaccines[J].Expert opinion on biological therapy,2018,18(7):765-784.

[24] Schlom J,Gulley J L.Vaccines as an integral component of cancer immunotherapy[J].Jama,2018,320(21):2195-2196.

[25] Zhu G,Mei L,Vishwasrao H D,et al.Intertwining DNA-RNA nanocapsules loaded with tumor neoantigens as synergistic nanovaccines for cancer immunotherapy[J].Nature communications,2017,8(1):1482.

[26] Schumacher T N,Schreiber R D.Neoantigens in cancer immunotherapy[J].Science,2015,348(6230):69-74.

[27] Vormehr M,Diken M,Boegel S,et al.Mutanome directed cancer immunotherapy[J].Current Opinion in Immunology,2016,39:14-22.

[28] Van Allen E M,Miao D,Schilling B,et al.Genomic correlates of response to CTLA-4 blockade in metastatic melanoma[J].Science,2015,350(6257):207-211.

[29] Rizvi N A,Hellmann M D,Snyder A,et al.Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer[J].Science,2015,348(6230):124-128.

[30] Le D T,Uram J N,Wang H,et al.PD-1 blockade in tumors with mismatch-repair deficiency[J].New England Journal of Medicine,2015,372(26):2509-2520.

[31] Evans R A,Diamond M S,Rech A J,et al.Lack of immunoediting in murine pancreatic cancer reversed with neoantigen[J].JCI insight,2016,1(14):e88328.

[32] Buettner M J,Shah S R,Saeui C T,et al.Improving immunotherapy through glycodesign[J].Frontiers in immunology,2018,9:1-29.

[33] Shimizu T,Lila A S A,Kawaguchi Y,et al.A novel platform for cancer vaccines:antigen-selective delivery to splenic marginal zone B cells via repeated injections of PEGylated liposomes[J].The Journal of Immunology,2018,201(10):2969-2976.

[34] Jaros?awski S,Toumi M.Sipuleucel-T (Provenge?)—Autopsy of an innovative paradigm change in cancer treatment:why a single-product biotech company failed to capitalize on its breakthrough invention[J].BioDrugs,2015,29(5):301-307.

[35] Ott P A,Hu Z,Keskin D B,et al.Corrigendum:an immunogenic personal neoantigen vaccine for patients with melanoma[J].Nature,2018,555(7696):402.

[36] Hanahan D,Weinberg R A.Hallmarks of cancer:the next generation[J].cell,2011,144(5):646-674.

[37] Sakurai D,Uchida R,Ihara F,et al.Immunosuppressive property of submandibular lymph nodes in patients with head and neck tumors:differential distribution of regulatory T cells[J].BMC research notes,2018,11(1):479.

[38] Vinay D S,Ryan E P,Pawelec G,et al.Immune evasion in cancer:Mechanistic basis and therapeutic strategies[C]//Seminars in cancer biology.Academic Press,2015,35:S185-S198.

[39] Wu S G,Liu Y N,Tsai M F,et al.The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients[J].Oncotarget,2016,7(11):12404.

[40] Jafarzadeh A,Nemati M,Khorramdelazad H,et al.Immunomodulatory properties of cimetidine:Its therapeutic potentials for treatment of immune-related diseases[J].International immunopharmacology,2019,70:156-166.

[41] Highfill S L,Cui Y,Giles A J,et al.Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy[J].Science translational medicine,2014,6(237):237-267.

[42] Deng G.Tumor-infiltrating regulatory T cells:origins and features[J].American journal of clinical and experimental immunology,2018,7(5):81-87.

[43] Barrow A D,Colonna M.Innate lymphoid cell sensing of tissue vitality[J].Current opinion in immunology,2019,56:82-93.

[44] Gao S,Yang D,Fang Y,et al.Engineering nanoparticles for targeted remodeling of the tumor microenvironment to improve cancer immunotherapy[J].Theranostics,2019,9(1):126-151.

[45] Tosolini M,Kirilovsky A,Mlecnik B,et al.Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1,th2,treg,th17) in patients with colorectal cancer[J].Cancer research,2011,71(4):1263-1271.

[46] Nagarsheth N,Wicha M S,Zou W.Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy[J].Nature Reviews Immunology,2017,17(9):559.

[47] Dalgleish A G.Rationale for combining immunotherapy with chemotherapy[J].Immunotherapy,2015,7(3):309-316.

[48] Wargo J A,Reuben A,Cooper Z A,et al.Immune effects of chemotherapy,radiation,and targeted therapy and opportunities for combination with immunotherapy[C]//Seminars in oncology.WB Saunders,2015,42(4):601-616.

[49] Sharabi A B,Lim M,DeWeese T L,et al.Radiation and checkpoint blockade immunotherapy:radiosensitisation and potential mechanisms of synergy[J].The lancet oncology,2015,16(13):e498-e509.

[50] Shahabi V,Postow M A,Tuck D,et al.Immune-priming of the tumor microenvironment by radiotherapy:rationale for combination with immunotherapy to improve anticancer efficacy[J].American journal of clinical oncology,2015,38(1):90-97.

[51] Teng F,Kong L,Meng X,et al.Radiotherapy combined with immune checkpoint blockade immunotherapy:achievements and challenges[J].Cancer letters,2015,365(1):23-29.

[52] Hughes P E,Caenepeel S,Wu L C.Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer[J].Trends in immunology,2016,37(7):462-476.

[53] Dunn J,Rao S.Epigenetics and immunotherapy:the current state of play[J].Molecular immunology,2017,87:227-239.

[54] Ledford H.Cocktails for cancer with a measure of immunotherapy[J].Nature News,2016,532(7598):162-164.